Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2016 Mar;22(3):292-7.
doi: 10.1093/icvts/ivv344. Epub 2015 Dec 15.

The impact of angiotensin II type 1 receptor antibodies on post-heart transplantation outcome in Heart Mate II bridged recipients

Marian Urban  1 , Antonij Slavcev  2 , Tomas Gazdic  3 , Peter Ivak  4 , Josef Besik  4 , Ivan Netuka  4
Affiliations
Observational Study

The impact of angiotensin II type 1 receptor antibodies on post-heart transplantation outcome in Heart Mate II bridged recipients

Marian Urban et al. Interact Cardiovasc Thorac Surg. 2016 Mar.

Abstract

Objectives: Antibodies targeting angiotensin II type 1 receptor (AT1R) have been associated with malignant hypertension, autoimmune diseases and acute rejection and graft loss in solid organ transplantation. The aim of our study was to assess the impact of anti-AT1R antibodies on survival and incidence of acute cellular rejection (ACR) and pathology antibody-mediated rejection (pAMR) in a population of heart transplant recipients who were bridged to transplantation with a durable mechanical assist device Heart Mate II.

Methods: Sera of 69 consecutive heart transplant recipients transplanted between October 2008 and August 2014 were tested for the presence of angiotensin II type 1 receptor antibodies before Heart Mate II device implantation and at the time of transplantation. Overall survival and post-transplant rejection-free survival were compared between antibody-negative and antibody-positive recipients using Kaplan-Meier and log-rank tests.

Results: Anti-AT1R antibodies were present in 8 patients (11.6%) before Heart Mate II implantation. During the left ventricular assist device (LVAD) bridging, 44 patients (63.8%) who were initially anti-AT1R antibody-negative became positive, leaving 17 (24.6%) anti-AT1R antibody-negative patients at the time of transplantation for all comparisons. One- and 5-year survival was 88 ± 8 and 76 ± 10% for anti-AT1R antibody-negative and 87 ± 5 and 81 ± 7% for anti-AT1R antibody-positive patients, respectively (P = 0.582). Freedom from ACR at 1 year was 68 ± 12% for anti-AT1R-negative and 75 ± 6% for anti-AT1R-positive recipients (P = 0.218). None of the anti-AT1R-negative patients developed AMR 1 year post-transplantation, whereas freedom from pAMR in anti-AT1R-positive recipients was 98 ± 2% (P = 0.198).

Conclusions: Our data showed no difference in the overall post-heart transplant survival and freedom from acute cellular and antibody-mediated rejection between anti-AT1R-negative and anti-AT1R-positive recipients. Further research is needed to assess the role of anti-AT1R antibodies in the risk stratification of LVAD-bridged recipients on the post-heart transplantation outcomes.

Keywords: Angiotensin II type 1 receptor; Heart transplantation; Mechanical circulatory support.

PubMed Disclaimer

Figures

Figure 1:
Figure 1:
Overall post-heart transplant survival stratified according to the presence of anti-AT1R antibodies before transplantation. AT1R: angiotensin II type 1 receptor.
Figure 2:
Figure 2:
Freedom from ACR ≥2R. AT1R: angiotensin II type 1 receptor; ACR: acute cellular rejection.
Figure 3:
Figure 3:
Freedom from pathology antibody-mediated rejection of any grade. AT1R: angiotensin II type 1 receptor.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Trivedi JR, Cheng A, Singh R, Williams ML, Slaughter MS. Survival on the heart transplant waiting list: impact of continuous flow left ventricular assist device as bridge to transplant. Ann Thorac Surg 2014;98:830–4. - PubMed
    1. Long EF, Swain GW, Mangi AA. Comparative survival and cost-effectiveness of advanced therapies for end-stage heart failure. Circ Heart Fail 2014;7:470–8. - PubMed
    1. Askar M, Hsich E, Reville P, Daghstani J, Nowacki A, Zhang A et al. . Comparison of HLA & MICA allosensitization patterns among patients supported by ventricular assist devices (VAD) and patients with no devices. J Heart Lung Transplant 2013;32:S74. - PubMed
    1. Askar M, Hsich E, Reville P, Nowacki AS, Baldwin W, Bakdash S et al. . HLA and MICA allosensitization patterns among patients supported by ventricular assist devices. J Heart Lung Transplant 2013;32:1241–8. - PubMed
    1. Banan B, Phelan D, Medhat A, Ewald G, Mohanakumar T. (47) - Increased sensitization to HLA and to cardiac self-antigens (myosin and vimentin) in patients waiting for cardiac transplantation with left ventricular assisting device (LVAD). J Heart Lung Transplant 2014;33:S25.

Publication types

MeSH terms